JP2015535283A - 癌療法における使用のためのトランス−クロミフェン - Google Patents

癌療法における使用のためのトランス−クロミフェン Download PDF

Info

Publication number
JP2015535283A
JP2015535283A JP2015540702A JP2015540702A JP2015535283A JP 2015535283 A JP2015535283 A JP 2015535283A JP 2015540702 A JP2015540702 A JP 2015540702A JP 2015540702 A JP2015540702 A JP 2015540702A JP 2015535283 A JP2015535283 A JP 2015535283A
Authority
JP
Japan
Prior art keywords
igf
clomiphene
subject
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015540702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535283A5 (enExample
Inventor
ジョセフ エス． ポドルスキ，
ジョセフ エス． ポドルスキ，
ロナルド ディー． ウィール，
ロナルド ディー． ウィール，
クアン シュー，
クアン シュー，
グレッグ フォンテノー，
グレッグ フォンテノー，
Original Assignee
レプロス セラピューティクス インコーポレイティド
レプロス セラピューティクス インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レプロス セラピューティクス インコーポレイティド, レプロス セラピューティクス インコーポレイティド filed Critical レプロス セラピューティクス インコーポレイティド
Publication of JP2015535283A publication Critical patent/JP2015535283A/ja
Publication of JP2015535283A5 publication Critical patent/JP2015535283A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015540702A 2012-11-02 2013-10-22 癌療法における使用のためのトランス−クロミフェン Withdrawn JP2015535283A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722013P 2012-11-02 2012-11-02
US61/722,013 2012-11-02
PCT/US2013/066141 WO2014070523A1 (en) 2012-11-02 2013-10-22 Trans-clomiphene for use in cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018094685A Division JP2018123168A (ja) 2012-11-02 2018-05-16 癌療法における使用のためのトランス−クロミフェン

Publications (2)

Publication Number Publication Date
JP2015535283A true JP2015535283A (ja) 2015-12-10
JP2015535283A5 JP2015535283A5 (enExample) 2016-09-29

Family

ID=50627954

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540702A Withdrawn JP2015535283A (ja) 2012-11-02 2013-10-22 癌療法における使用のためのトランス−クロミフェン
JP2018094685A Pending JP2018123168A (ja) 2012-11-02 2018-05-16 癌療法における使用のためのトランス−クロミフェン
JP2020216526A Pending JP2021046448A (ja) 2012-11-02 2020-12-25 癌療法における使用のためのトランス−クロミフェン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018094685A Pending JP2018123168A (ja) 2012-11-02 2018-05-16 癌療法における使用のためのトランス−クロミフェン
JP2020216526A Pending JP2021046448A (ja) 2012-11-02 2020-12-25 癌療法における使用のためのトランス−クロミフェン

Country Status (10)

Country Link
US (1) US9687458B2 (enExample)
EP (1) EP2914294A1 (enExample)
JP (3) JP2015535283A (enExample)
CN (1) CN104994877A (enExample)
AU (1) AU2013338311A1 (enExample)
CA (1) CA2889770A1 (enExample)
HK (1) HK1216502A1 (enExample)
IL (1) IL238453A0 (enExample)
MX (1) MX2015005160A (enExample)
WO (1) WO2014070523A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018003829A1 (ja) * 2016-06-29 2018-01-04 国立大学法人東京大学 オートファジー阻害剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170217914A1 (en) * 2014-08-05 2017-08-03 The Penn State Research Foundation Novel Triarylethylene Compounds and Methods Using Same
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
US20200030259A1 (en) * 2016-09-26 2020-01-30 Repros Therapeutics Inc. Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms
CN108420806A (zh) * 2017-02-15 2018-08-21 武汉华杰世纪生物医药有限公司 具有靶向性的抗肿瘤药物
WO2019236209A2 (en) * 2018-04-27 2019-12-12 Jin Byung Ju Methods for high-content drug screening

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
JP2008534503A (ja) * 2005-03-22 2008-08-28 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
JP2009545724A (ja) * 2006-06-30 2009-12-24 シェーリング コーポレイション Ｉｇｆｂｐ２インヒビター
WO2010054248A1 (en) * 2008-11-07 2010-05-14 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3660489D1 (en) 1985-06-08 1988-09-15 Asta Pharma Ag Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
AU672234B2 (en) 1992-09-15 1996-09-26 Merrell Dow Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
CA2192708A1 (en) 1994-06-17 1995-12-28 Kenneth J. Himmelstein In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
WO1997006787A2 (en) 1995-08-17 1997-02-27 Dyer, Alison, Margaret Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
NZ500649A (en) 1997-04-03 2001-05-25 Guilford Pharm Inc Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU779398B2 (en) 1998-07-30 2005-01-20 Stoller Enterprises, Inc. Treatment of plants with salicylic acid and organic amines
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200200406T2 (tr) 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
EP1289519B1 (en) 2000-05-26 2019-02-13 Harry Fisch Methods of treating androgen deficiency in men using clomiphene
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
PT1318837E (pt) 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002213198A1 (en) 2000-10-11 2002-04-22 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
CN1954807A (zh) 2001-07-09 2007-05-02 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
NZ556499A (en) 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US20080306035A1 (en) 2005-08-05 2008-12-11 Repros Therapeutics Inc. Methods and Compositions for Treating Female Infertility Using Clomiphene
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
JP2009527504A (ja) 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
WO2009000306A1 (en) 2007-06-26 2008-12-31 Soporte Multivendor S.L. Method and device for managing multicast groups
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
EP2819676B1 (en) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
CA2880388A1 (en) 2012-08-21 2014-02-27 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019916A1 (en) * 2004-07-14 2006-02-23 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
JP2008534503A (ja) * 2005-03-22 2008-08-28 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
JP2009545724A (ja) * 2006-06-30 2009-12-24 シェーリング コーポレイション Ｉｇｆｂｐ２インヒビター
WO2010054248A1 (en) * 2008-11-07 2010-05-14 Repros Therapeutics Inc. Trans-clomiphene for metabolic syndrome and diabetes mellitus type 2

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CANCER BIOLOGY & THERAPY, vol. Vol.11(8), JPN6017020371, 2011, pages 701 - 707, ISSN: 0003720501 *
CANCER BIOLOGY & THERAPY, vol. Vol.2(6), JPN6017020370, 2003, pages 630 - 635, ISSN: 0003720500 *
CANCER RESERCH, vol. 57, JPN6017020364, 1997, pages 2687 - 2693, ISSN: 0003720497 *
FERTILITY AND STERILITY, vol. Vol.63(6), JPN6017020368, 1995, pages 1200 - 1203, ISSN: 0003720499 *
HUMAN REPRODUCTION, vol. Vol.15(11), JPN6017020366, 2000, pages 2302 - 2305, ISSN: 0003720498 *
J. ANDROL., vol. Vol.15(5), JPN6018023168, 1994, pages 449 - 455, ISSN: 0003821483 *
J. CLIN. ENDOCRINOL. METAB., vol. Vol.77(3), JPN6018023166, 1993, pages 776 - 779, ISSN: 0003821482 *
NAT. REV. ENDOCRINOL., vol. 7, JPN6017020359, 2011, pages 11 - 24, ISSN: 0003720495 *
NOVARTIS FOUNDATION SYMPOSIUM 262 BIOLOGY OF IGF-1:ITS INTERACTION WITH INSULIN IN HEALTH AND MALIGN, JPN6017020361, 2004, pages 247 - 264, ISSN: 0003720496 *
PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 35, JPN6017020372, 1994, pages 267 - 1593, ISSN: 0003720494 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018003829A1 (ja) * 2016-06-29 2018-01-04 国立大学法人東京大学 オートファジー阻害剤

Also Published As

Publication number Publication date
WO2014070523A1 (en) 2014-05-08
EP2914294A1 (en) 2015-09-09
US20150283099A1 (en) 2015-10-08
JP2021046448A (ja) 2021-03-25
IL238453A0 (en) 2015-06-30
CA2889770A1 (en) 2014-05-08
AU2013338311A1 (en) 2015-05-14
CN104994877A (zh) 2015-10-21
JP2018123168A (ja) 2018-08-09
MX2015005160A (es) 2015-07-17
HK1216502A1 (zh) 2016-11-18
US9687458B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
JP5856652B2 (ja) メタボリック症候群用のｔｒａｎｓ−クロミフェン
JP2018123168A (ja) 癌療法における使用のためのトランス−クロミフェン
TWI458478B (zh) 用於代謝症候群與第２型糖尿病的反式氯米芬
US20050272717A1 (en) Treatment of aromatase inhibitor therapy-related osteoporosis
US20130165524A1 (en) Trans-clomiphene for metabolic syndrome
JP6417409B2 (ja) 骨塩密度を増加させる薬剤としてのトランス−クロミフェン及びその類似体
AU2008314538B2 (en) Trans-clomiphene for metabolic syndrome
HK1150023B (en) Trans-clomiphene for metabolic syndrome
HK1182618A (en) Trans-clomiphene for metabolic syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20180622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200803